Crestor Pharmacokinetics (ADME): How Rosuvastatin Is Absorbed, Distributed, Metabolized, and Eliminated

Mechanism of Action: Selective HMG-CoA Reductase Inhibition

Rosuvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. By blocking the conversion of HMG-CoA to mevalonate, the drug depletes intracellular cholesterol pools and triggers upregulation of LDL receptors on hepatocyte surfaces [1]. The net result is increased clearance of LDL-C from the bloodstream.

What separates rosuvastatin from earlier statins is its binding affinity. X-ray crystallography data published by Istvan and Deisenhofer in Science demonstrated that rosuvastatin forms a greater number of binding interactions with the HMG-CoA reductase catalytic site than atorvastatin or simvastatin [2]. This tighter binding partly explains why rosuvastatin produces larger LDL-C reductions on a milligram-for-milligram basis. The STELLAR trial (N=2,431) confirmed that rosuvastatin 10 mg to 40 mg lowered LDL-C by 46% to 55%, compared with 37% to 51% for atorvastatin 10 mg to 80 mg across matched dose ranges [3]. Rosuvastatin is administered as the active hydroxy acid form and does not require hepatic conversion from a lactone prodrug, unlike simvastatin and lovastatin. This matters pharmacokinetically because it removes a variable activation step.

The JUPITER trial (N=17,802) validated the clinical significance of this potent LDL-lowering: rosuvastatin 20 mg reduced major cardiovascular events by 44% in apparently healthy adults with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein [4].

Absorption: Oral Bioavailability and the Role of Hepatic First-Pass Uptake

Rosuvastatin's absolute bioavailability is approximately 20%, a figure driven primarily by efficient first-pass hepatic extraction rather than poor intestinal absorption [1]. The drug is absorbed along the length of the gastrointestinal tract, with peak plasma concentrations reached at a median of 3 to 5 hours after oral dosing.

Food does not meaningfully alter rosuvastatin's area under the curve (AUC). The FDA-approved prescribing information notes that co-administration with food decreased Cmax by about 20% but did not change AUC, making the drug suitable for administration without regard to meals [1]. This contrasts with fluvastatin extended-release, where food significantly increases absorption.

An often-overlooked point: rosuvastatin is hydrophilic (log P = −0.33), which limits passive transcellular diffusion across hepatocyte membranes [5]. Instead, hepatic uptake depends almost entirely on active transport via organic anion-transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) and OATP1B3. This transporter dependence has direct clinical consequences, discussed in the drug-interaction section below.

Antacid co-administration (aluminum and magnesium hydroxide combinations) reduces rosuvastatin Cmax and AUC by approximately 50% when given simultaneously. The prescribing information recommends spacing antacids at least 2 hours after rosuvastatin dosing [1]. Clinicians managing patients on chronic proton pump inhibitors can reassure them: PPIs do not share this interaction.

Distribution: Hepatoselectivity and Protein Binding

Rosuvastatin distributes with high selectivity to the liver, its target organ. Studies using radiolabeled rosuvastatin demonstrated that the liver accounts for roughly 90% of total drug uptake, a degree of hepatoselectivity exceeding that of atorvastatin and simvastatin [6]. This preferential hepatic distribution is, again, mediated by OATP1B1 and OATP1B3 transporters on the sinusoidal membrane of hepatocytes.

Plasma protein binding sits at approximately 88%, predominantly to albumin [1]. The apparent volume of distribution is roughly 134 liters, reflecting extensive tissue uptake beyond the plasma compartment. Because the drug concentrates in the liver and has limited penetration of peripheral tissues (including skeletal muscle), the ratio of muscle-to-liver exposure is low. Some pharmacologists have hypothesized that this distribution profile contributes to rosuvastatin's relatively favorable myotoxicity profile at standard doses, though head-to-head myopathy incidence data across statins remain limited [7].

Rosuvastatin does not cross the blood-brain barrier to a clinically meaningful extent. Its hydrophilicity limits passive diffusion across tight junctions of the cerebral endothelium. This characteristic has been cited in discussions about statin-associated cognitive complaints, although the 2012 FDA safety communication on statins and cognition did not differentiate risk by lipophilicity [8].

Metabolism: CYP2C9 and the N-Desmethyl Metabolite

Rosuvastatin undergoes minimal hepatic metabolism. This is a distinguishing pharmacokinetic feature. Approximately 10% of a radiolabeled dose is recovered as metabolites, leaving roughly 90% as unchanged parent drug [1].

The principal metabolic pathway involves CYP2C9-mediated N-demethylation, producing N-desmethyl rosuvastatin [1]. This metabolite retains HMG-CoA reductase inhibitory activity but at approximately one-sixth the potency of the parent compound, and it circulates at concentrations low enough that its clinical contribution is considered negligible. A second minor metabolite, rosuvastatin lactone, is formed via non-enzymatic lactonization and has minimal pharmacologic activity.

The limited CYP450 involvement has practical implications. Rosuvastatin avoids the extensive CYP3A4-mediated metabolism that creates interaction risks for simvastatin and lovastatin with azole antifungals, macrolide antibiotics, and protease inhibitors [9]. Dr. Robert Rosenson, a lipidologist at the Icahn School of Medicine at Mount Sinai, has noted: "Rosuvastatin's minimal CYP3A4 metabolism makes it a preferred statin when patients require concurrent therapy with potent CYP3A4 inhibitors, such as itraconazole or ritonavir."

CYP2C9 polymorphisms exist but have not been shown to produce clinically relevant changes in rosuvastatin exposure. The 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for statins focused its rosuvastatin recommendations on SLCO1B1 and ABCG2 transporter variants rather than CYP2C9 genotype [10].

Elimination: Biliary Excretion and the 19-Hour Half-Life

Biliary excretion is the dominant elimination pathway. About 90% of an orally administered dose is recovered in feces (as absorbed drug excreted via bile plus unabsorbed drug), while approximately 10% appears in urine [1]. Renal clearance contributes modestly, estimated at about 50 mL/min.

The elimination half-life of rosuvastatin is approximately 19 hours [1]. This is substantially longer than the 1 to 3 hour half-life of fluvastatin or the 2 to 3 hour half-life of pravastatin, and it explains why rosuvastatin can be taken at any time of day without loss of efficacy. Short-acting statins like simvastatin are preferentially dosed in the evening because hepatic cholesterol synthesis peaks during overnight fasting hours; rosuvastatin's long half-life provides sustained enzyme inhibition regardless of dosing time.

Steady-state plasma concentrations are achieved within approximately 5 days of once-daily dosing, consistent with a 19-hour half-life (roughly 5 half-lives to reach steady state). The accumulation ratio is modest, with AUC at steady state approximately 1.5-fold higher than after a single dose.

In patients with moderate renal impairment (creatinine clearance 30 to 60 mL/min), rosuvastatin AUC increases approximately 3-fold compared with healthy subjects [1]. The prescribing information recommends a starting dose of 5 mg in patients with severe renal impairment (creatinine clearance <30 mL/min, not on hemodialysis) and limits the maximum dose to 10 mg daily in this group.

Transporter-Mediated Drug Interactions: OATP1B1, BCRP, and Clinical Consequences

The most clinically significant pharmacokinetic interactions with rosuvastatin involve membrane transporters, not CYP enzymes. Three transporters deserve specific attention.

OATP1B1 (SLCO1B1). This hepatic uptake transporter governs rosuvastatin entry into hepatocytes. Drugs that inhibit OATP1B1, including cyclosporine, gemfibrozil, and certain protease inhibitors, can substantially increase rosuvastatin plasma concentrations. Cyclosporine co-administration increases rosuvastatin AUC by approximately 7-fold, and the combination is contraindicated at rosuvastatin doses above 5 mg [1]. Gemfibrozil raises rosuvastatin AUC roughly 2-fold [11].

BCRP (ABCG2). Breast cancer resistance protein mediates intestinal efflux and biliary secretion of rosuvastatin. Inhibitors of BCRP (including eltrombopag and certain tyrosine kinase inhibitors) can increase systemic exposure. The ABCG2 c.421C>A polymorphism (rs2231142) reduces BCRP function and has been associated with 1.4 to 2.4-fold increases in rosuvastatin AUC across multiple pharmacogenomic studies [10].

OATP1B3. Functions alongside OATP1B1 for hepatic uptake. Dual inhibition of both OATP1B1 and OATP1B3 produces the largest increases in systemic rosuvastatin exposure.

The 2022 CPIC guideline assigns specific rosuvastatin prescribing recommendations based on SLCO1B1 and ABCG2 genotype [10]. Patients carrying the SLCO1B1 521T>C poor-function variant (rs4149056) who are also ABCG2 421C>A carriers may require dose reductions or closer monitoring for myopathy. The guideline specifically recommends a rosuvastatin dose not exceeding 20 mg daily for SLCO1B1 poor-function carriers.

Dr. Marc Sabatine, chair of the TIMI Study Group at Brigham and Women's Hospital, commented on the clinical relevance of pharmacogenomics in statin prescribing: "For rosuvastatin, the SLCO1B1 genotype matters more for predicting adverse effects than CYP polymorphisms. This is fundamentally different from simvastatin, where CYP3A4 interactions dominate the risk profile."

Special Populations: Hepatic Impairment, Asian Ancestry, and Age

Hepatic impairment significantly alters rosuvastatin pharmacokinetics. In patients with Child-Pugh class A (mild) cirrhosis, Cmax and AUC increase modestly. In Child-Pugh class B or C, increases of approximately 5-fold and 3-fold in Cmax and AUC respectively have been reported, and rosuvastatin is contraindicated in active liver disease [1].

Pharmacokinetic studies in subjects of Asian ancestry demonstrated approximately 2-fold higher median AUC compared with white subjects when administered the same rosuvastatin dose [1]. This finding led the FDA to require a specific labeling recommendation: the starting dose for Asian patients should be 5 mg once daily. The mechanism likely involves higher prevalence of reduced-function ABCG2 and SLCO1B1 alleles in East Asian populations, though other pharmacogenomic and environmental factors may contribute [12].

Age-related changes are minimal. Rosuvastatin AUC in elderly subjects (65 years and older) is approximately 1.3-fold higher than in younger adults, a difference not considered clinically significant enough to require routine dose adjustments [1]. Pediatric pharmacokinetic data from heterozygous familial hypercholesterolemia trials support weight-based dosing consistency in children aged 8 to 17 years.

Rosuvastatin vs. Other Statins: Pharmacokinetic Comparison

Rosuvastatin occupies a distinct position in the statin pharmacokinetic spectrum. Its hydrophilicity (similar to pravastatin, contrasting with the lipophilic atorvastatin, simvastatin, and lovastatin) limits passive membrane diffusion and concentrates drug action at the liver through transporter-dependent uptake [5]. The 19-hour half-life exceeds that of every statin except atorvastatin (approximately 14 hours for the parent compound, though active metabolites extend effective duration).

The minimal CYP3A4 involvement gives rosuvastatin a narrower drug-interaction profile than atorvastatin for CYP3A4-mediated interactions, while atorvastatin maintains an advantage in not requiring the same degree of transporter-interaction vigilance. Both drugs allow flexible dosing time, a practical advantage over simvastatin, which the FDA specifically recommends for evening dosing [9].

Bioavailability across the statin class ranges from 5% (simvastatin, lovastatin) to approximately 34% (pitavastatin). Rosuvastatin's 20% sits mid-range but delivers the highest LDL-lowering per milligram of absorbed drug, reflecting its superior binding kinetics at the enzyme active site [2][3].

Clinical Relevance of Rosuvastatin's ADME Profile

Every pharmacokinetic parameter described above translates to a bedside decision. The 19-hour half-life means morning or evening dosing works equally well, improving adherence for patients who dislike bedtime pill schedules. Hydrophilicity and transporter-dependent hepatic uptake mean fewer CYP-mediated interactions but greater sensitivity to OATP1B1/BCRP inhibitors and genetic variants in SLCO1B1 and ABCG2. Clinicians prescribing cyclosporine, gemfibrozil, or certain antiretrovirals alongside rosuvastatin must reduce the dose or choose an alternative statin.

For patients of East Asian ancestry, the labeled 5 mg starting dose reflects real pharmacokinetic differences, not a population-level generalization without data. The 2022 CPIC guideline offers genotype-specific dosing for any patient with available pharmacogenomic results, regardless of self-reported ancestry [10].

The recommended starting dose for most adults is 10 mg to 20 mg once daily, with a maximum of 40 mg reserved for patients not reaching LDL-C targets at 20 mg and who are not in a high-risk transporter-interaction category [1].